Education
About Us
Working with TipRanks
Follow Us
iCAD Inc (ICAD)
:ICAD
ICAD Stock Chart & Stats
$3.87
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iCAD News
ICAD FAQ
What was iCAD Inc’s price range in the past 12 months?
Currently, no data Available
What is iCAD Inc’s market cap?
Currently, no data Available
When is iCAD Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iCAD Inc’s earnings last quarter?
Currently, no data Available
Is iCAD Inc overvalued?
According to Wall Street analysts iCAD Inc’s price is currently Undervalued.
Does iCAD Inc pay dividends?
iCAD Inc does not currently pay dividends.
What is iCAD Inc’s EPS estimate?
iCAD Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iCAD Inc have?
Currently, no data Available
What happened to iCAD Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of iCAD Inc?
Currently, no hedge funds are holding shares in ICAD
Company Description
iCAD Inc
iCAD, Inc. is a global medical technology company that provides innovative cancer detection and therapy solutions. The company operates primarily in the sectors of cancer detection, breast cancer risk assessment, and cancer therapy. Its core products include advanced image analysis and workflow solutions for mammography and radiation therapy for cancer treatment. iCAD's technologies are designed to enhance the detection and treatment of cancer, thereby improving patient outcomes and the efficiency of healthcare providers.
Ownership Overview
―
Insiders
4.41%
Mutual Funds
― Other Institutional Investors
95.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---